Investors who purchased securities in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) and suffered financial losses are facing an investigation. Initiated by the law firm Kessler Topaz Meltzer & Check, LLP, the probe follows a sharp 28% stock drop triggered by lowered full-year 2026 sales guidance and disappointing second-quarter results.
The announcement from Alnylam Pharmaceuticals on July 30, 2026, laid bare a significant adjustment in corporate expectations. According to the company’s second-quarter financial report, management lowered TTR product sales guidance for the full year 2026 by approximately $200 million. This adjustment, as stated by the company, stems from learnings during the initial commercial launch phase within the evolving ATTR-CM market—specifically noting a normalization of growth in second-line volume once initial pent-up demand from patients waiting for new therapies had been satisfied.
In Alnylam’s case, the revelation caused the company’s stock price to plummet by over 28%. Consequently, legal entities such as Kessler Topaz Meltzer & Check, LLP have stepped forward to evaluate whether federal securities laws were violated during the period leading up to these disclosures, offering affected investors a channel to review their legal standing at no upfront cost.
In the context of ATTR-CM and hereditary ATTR amyloidosis with polyneuropathy, these therapies target the hepatic synthesis of transthyretin, effectively halting the pathogenic cascade at the molecular level.
| Metric | Reported Data (Q2 2026) | Market Impact |
|---|---|---|
| Guidance Revision | Reduced full-year 2026 TTR net product revenue by ~$200 million | Stock price decline exceeding 28% |
| Primary Market Factor | Normalization of second-line volume after initial pent-up demand | Re-evaluation of commercial growth curves |
| Legal Response | Kessler Topaz Meltzer & Check, LLP investigation | Securities litigation review for impacted investors |
References
- Business Wire / Morningstar: “NASDAQ: ALNY Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. Investors to Contact the Firm,” August 2026.
- AI Journ: Coverage of Kessler Topaz Meltzer & Check, LLP Investigation into Alnylam Pharmaceuticals, Inc., August 2026.
- U.S.
